Report overview
Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.
This report contains market size and forecasts of Chronic Idiopathic Constipation (CIC) Drugs in global, including the following market information:
Global Chronic Idiopathic Constipation (CIC) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Chronic Idiopathic Constipation (CIC) Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Chronic Idiopathic Constipation (CIC) Drugs companies in 2021 (%)
The global Chronic Idiopathic Constipation (CIC) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Lubiprostone Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chronic Idiopathic Constipation (CIC) Drugs include Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chronic Idiopathic Constipation (CIC) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Chronic Idiopathic Constipation (CIC) Drugs Market Segment Percentages, by Type, 2021 (%)
Lubiprostone
Linaclotide
Others
Global Chronic Idiopathic Constipation (CIC) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Chronic Idiopathic Constipation (CIC) Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals & Clinics
Ambulatory Surgical Centres
Long Term Care Centres
Others
Global Chronic Idiopathic Constipation (CIC) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Chronic Idiopathic Constipation (CIC) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chronic Idiopathic Constipation (CIC) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Chronic Idiopathic Constipation (CIC) Drugs revenues share in global market, 2021 (%)
Key companies Chronic Idiopathic Constipation (CIC) Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Chronic Idiopathic Constipation (CIC) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Actavis
Chugai Pharmaceutical
Ferring International Center
Synergy Pharmaceuticals
Pfizer
GlaxoSmithKline
Roche Holding
Sanofi
Bayer
Salix Pharmaceuticals
Sucampo Pharmaceuticals
Ironwood Pharmaceuticals
Progenics Pharmaceuticals
